AlzeCure Pharma AB is a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease. AlzeCure Pharma is pursuing five primary drug candidates within the two main research programs, NeuroRestore och Alzstatin.

The NeuroRestore program contains symptomatic treatments including the primary drug candidate, ACD855, which is planned for clinical Phase I studies in December 2018. The second program, Alzstatin, contains disease modifying and preventive treatments.

A diversified portfolio that addresses key signaling pathways in the brain, enables also a range of other indications are possible, e.g. cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease.